NCT03546452View on ClinicalTrials.gov

A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLC

UnknownOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

May 18, 2018

Primary Completion Date

September 30, 2018

Study Completion Date

May 1, 2019

Conditions
Malignant HydrothoraxNSCLC
Interventions
DIAGNOSTIC_TEST

in vitro NGS-panel

cell free DNA ,which was purified from hydrothorax, is used to be tested by NGS-panel

Trial Locations (1)

200030

RECRUITING

Shangha Chest Hospital, Shanghai

Sponsors

Collaborators (1)

Amoy Diagnostics
All Listed Sponsors
collaborator

Sinotech Genomics Co., Ltd

UNKNOWN

collaborator

Amoy Diagnostics

INDUSTRY

collaborator

Guangzhou Burning Rock Medical Examination Institute Co., Ltd.

INDUSTRY

collaborator

Geneplus-Beijing Co. Ltd.

INDUSTRY

collaborator

Berry Genomics Co., Ltd.

INDUSTRY

lead

Shanghai Chest Hospital

OTHER

NCT03546452 - A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLC | Biotech Hunter | Biotech Hunter